The many worlds of reducing interleukin‐1
Open Access
- 28 June 2005
- journal article
- editorial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 52 (7) , 1960-1967
- https://doi.org/10.1002/art.21107
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Soluble interleukin‐1 receptor accessory protein ameliorates collagen‐induced arthritis by a different mode of action from that of interleukin‐1 receptor antagonistArthritis & Rheumatism, 2005
- Rapid responses to anakinra in patients with refractory adult‐onset Still's diseaseArthritis & Rheumatism, 2005
- Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor AntagonistsClinical Infectious Diseases, 2004
- Intracellular Interleukin-1α Functionally Interacts with Histone Acetyltransferase ComplexesJournal of Biological Chemistry, 2004
- A Pilot Trial of External Qigong Therpy for ArthritisJCR: Journal of Clinical Rheumatology, 2003
- Anakinra, a recombinant human interleukin‐1 receptor antagonist (r‐metHuIL‐1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo‐controlled trialArthritis & Rheumatism, 2003
- Interleukin‐1β, but not interleukin‐1α, is required for T‐cell‐dependent antibody productionImmunology, 2001
- IL-1α, but not IL-1β, is required for contact-allergen-specific T cell activation during the sensitization phase in contact hypersensitivityInternational Immunology, 2001
- Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein.Journal of Clinical Investigation, 1997
- Interleukin-1 Type II Receptor: A Decoy Target for IL-1 That Is Regulated by IL-4Science, 1993